Veterinary Medicines Directorate

Woodham Lane, New Haw, Addlestone, Surrey KT15 3LS
Telephone +44 (0)1932 336911

Post Authorisation Assessments

Enterisol Ileitis Lyophilisate and Solvent for Oral Suspension for Pigs

Vm 61700/5000

19 August 2026	One-off alignment of the product information with the national product information template v. 3.
03 June 2026	To delete a site for finished product testing.
14 January 2026	To update the name of a supplier and the certificate of suitability for a starting material
28 November 2025	Change of legal entity of the Marketing Authorisation Holder from Boehringer Ingelheim Animal Health UK Limited, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS, United Kingdom to Boehringer Ingelheim Vetmedica GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany.
14 November 2025	Addition of an additional site for finished product testing.
19 January 2025	Approval of mock ups for the 100-dose pack size.
17 January 2025	With the present grouping procedure, the MAH is proposing two variations regarding newborn bovine calf serum. The first is to update the CEP of the Cytiva supplier to the new version. With the present grouping procedure, the MAH is proposing two variations regarding newborn bovine calf serum. The second is to add a supplementary CEP for SAFC supplier.
31 October 2024	Change in the address of the finished product testing site.
17 July 2024	Replace the current company preparing and testing the 10 X porcine trypsin solution with Boehringer Ingelheim company that will use the current porcine trypsin source and solution recipe. Expand the geographical sourcing for porcine trypsin. Add a new foetal bovine serum supplier holding a valid CEP. (GB)
13 April 2024	Editorial changes to part 2B of the dossier.
27 February 2024	Change in the specification parameters of a starting material used in the manufacturing process of the active substance. (GB)
18 July 2023	To use recombinant non-animal origin trypsin as an alternative to porcine origin trypsin during the dissociation of McCoy cell line.
11 April 2023	Change in the name or address or contact details of a qualified person for pharmacovigilance.
15 March 2023	To make changes in the manufacturing process of the finished product by standardising the fill line set-ups with the installation of a 225-micron stainless steel mesh screen inline between the blending and filling lines
19 January 2023	The aim of this variation is the introduction of an optional sterile in-line screen mesh clarification system between the blending vessel and the filling lines of the manufacturing process of the modified live vaccines, Bovela, Enterisol Ileitis, Ingelvac PRRSFLEX EU, and ReproCyc PRRS.

24 October 2022	Optimisation of the cell planting procedure for the antigen quantification test. Optimisation of the cell planting procedure for the finished product batch release potency test.
24 September 2021	Change in the name of the manufacturer of the finished product.
04 March 2021	Change in the SPC, labelling or package leaflet due to new data.
14 January 2021	Submission of an updated Ph. Eur. TSE certificate of suitability for a starting material from an already approved manufacturer. Submission of an updated Ph. Eur. TSE certificate of suitability for a starting material from an already approved manufacturer.
19 August 2020	Change in the name of the manufacturer of the finished product. Deletion of the diluent container from the pack.
09 October 2019	Change in the name of a manufacturer of active substance used in the manufacture of the active substance. Change in the name of the manufacturer of the finished product. Submission of an updated Ph. Eur. TSE certificate of suitability from an already approved manufacturer. Submission of an updated Ph. Eur. TSE certificate of suitability from an already approved manufacturer. Submission of an updated Ph. Eur. TSE certificate of suitability from an already approved manufacturer. Submission of an updated Ph. Eur. TSE certificate of suitability from an already approved manufacturer. Submission of an updated Ph. Eur. TSE certificate of suitability from an already approved manufacturer.
24 September 2019	Change in the safety database of an existing pharmacovigilance system as described in the DDPS.
06 March 2019	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.
07 November 2018	Change of MAH, from Boehringer Ingelheim Ltd, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS to Boehringer Ingelheim Animal Health UK Ltd, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS.
23 October 2018	Changes to the labelling and package leaflet.
05 December 2017	Deletion of a manufacturing site for an active substance. Replacement of a secondary packaging site of the finished product
13 June 2017	Minor change to an approved test procedure for the active substance.
24 February 2017	Repeat Use application to add one new member state
10 February 2017	Deletion of a test procedure used in the manufacturing process of the active substance. Deletion of a test procedure used in the manufacturing process of the active substance. Deletion of a test procedure used in the manufacturing process of the active substance. Submission of a new Ph. Eur. TSE certificate of suitability from a new manufacturer. Widening of the specification limits used in the manufacturing process of the active substance. Submission of a new Ph. Eur. TSE certificate of suitability from a new manufacturer. Submission of a new Ph. Eur. TSE certificate of suitability from a new manufacturer.

	Submission of a new Ph. Eur. TSE certificate of suitability from a new manufacturer.
15 December 2016	Change in the SPC, labelling or package leaflet due to new data.
04 November 2016	Change in address of the Polish local representative.
12 July 2016	Revision of the primary packaging documentation
11 January 2016	Minor changes to the identification/potency test method Minor changes to the extraneous agents test method
12 November 2015	Introduction of a new pharmacovigilance system
14 July 2015	Repeat use procedure.
01 July 2015	Addition of an alternative site for secondary packaging.
05 January 2015	Submission of updated Ph. Eur. Certificates of Suitability.
24 September 2012	Addition of a manufacturing site for secondary packaging
05 January 2012	Change of address of the MAH
17 December 2009	Renewal
09 January 2008	Change of suppliers of a starting material used in the manufacture of the active substance Submission of an updated Ph. Eur. Certificate of Suitability for a starting material used in the manufacture of the active substance
19 December 2007	Corrections to the SPC and change of legal category to POM-V
26 July 2007	Removal of target animal safety test
13 February 2006	Change of batch size of finished product
01 September 2005	Change of shelf life for 100 dose presentation from 1 year to 2 years